| [1] |
Black D.Familial breast cancer.BRCA1 down, BRCA2 to go[J].Curr Biol,1994,4(11):1023-1024.
|
| [2] |
Bishop DT.BRCA1, BRCA2, BRCA3… a myriad of breast cancer genes[J].Eur J Cancer,1994,30A(12):1738-1739.
|
| [3] |
Barnes DR, Antoniou AC.Unravelling modifiers of breast and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers:update on genetic modifiers[J].J Intern Med,2012,271(4):331-343.
|
| [4] |
Metcalfe K, Lynch HT, Ghadirian P, et al.Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers[J].Breast Cancer Res Treat,2011,127(1):287-296.
|
| [5] |
鲁培荣,谭敏,宾晓农,等.散发性乳腺癌BRCA1 和BRCA2基因突变分析[J/CD].中华乳腺病杂志:电子版, 2009,3(3):317-328.
|
| [6] |
Easton DF, Ford D, Bishop DT.Bishop, Breast and ovarian cancer incidence in BRCA1-mutation carriers.Breast Cancer Linkage Consortium[J].Am J Hum Genet,1995,56(1):265-271.
|
| [7] |
Verna EC, Hwang C, Stevens PD, et al.Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics [J].Clin Cancer Res,2010,16(20):5028-5037.
|
| [8] |
De Luca P, Vazquez ES, Moiola CP, et al.BRCA1 loss induces GADD153-mediated doxorubicin resistance in prostate cancer[J].Mol Cancer Res,2011,9(8):1078-1090.
|
| [9] |
Roy R, Chun J, Powell SN.BRCA1 and BRCA2: different roles in a common pathway of genome protection[J].Nat Rev Cancer,2011,12(1):68-78.
|
| [10] |
Weber BL, Abel KJ, Couch FJ, et al.Transcript identification in the BRCA1 candidate region[J].Breast Cancer Res Treat,1995,33(2):115-124.
|
| [11] |
Foulkes WD.Traffic control for BRCA1[J].N Engl J Med,2010,362(8):755-756.
|
| [12] |
Huber LJ, Chodosh LA.Dynamics of DNA repair suggested by the subcellular localization of Brca1 and Brca2 proteins[J].J Cell Biochem,2005,96(1):47-55.
|
| [13] |
Nadeau G,Boufaied N,Moisan A,et al.BRCA1 can stimulate gene transcription by a unique mechanism[J].EMBO Rep,2000,1(3):260-265.
|
| [14] |
De Siervi A, De Luca P, Byun JS, et al.Transcriptional autoregulation by BRCA1[J].Cancer Res, 2010,70(2):532-542.
|
| [15] |
Nguyen D, Zajac-Kaye M, Rubinstein L, et al.Poly(ADPribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent[J].Cell Cycle,2011,10(23):4074-4082.
|
| [16] |
Privat M, Aubel C, Arnould S, et al.AKT and p21 WAF1/CIP1 as potential genistein targets in BRCA1-mutant human breast cancer cell lines[J].Anticancer Res,2010,30(6):2049-2054.
|
| [17] |
李波,华彬.乳腺癌BARD1 基因研究的现状[J/CD].中华乳腺病杂志:电子版,2010,4(5):554-557.
|
| [18] |
Gudmundsdottir K, Ashworth A.The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability[J].Oncogene,2006,25(43):5864-5874.
|
| [19] |
Tercyak KP, Peshkin BN, Brogan BM, et al.Quality of life after contralateral prophylactic mastectomy in newly diagnosed high-risk breast cancer patients who underwent BRCA1/2 gene testing[J].J Clin Oncol,2007,25(3):285-291.
|
| [20] |
Xie ZM, Li LS, Laquet C, et al.Germline mutations of the Ecadherin gene in families with inherited invasive lobular breast carcinoma but no diffuse gastric cancer[J].Cancer, 2011,117(14): 3112-3117.
|
| [21] |
No authors listed.Sitting up and taking notice [J].Nat Biotechnol,2010,28(5):381.
|
| [22] |
Lee LJ, Alexander B, Schnitt SJ, et al.Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers[J].Cancer,2011,117(14):3093-3100.
|
| [23] |
Loman N, Borg A.Improving surveillance and quality of life of BRCA mutation carriers[J].J Clin Oncol, 2010,28(22):e376-377.
|
| [24] |
Chappuis PO,Kapusta L,Bégin LR,et al.Germline BRCA1/2 mutations and p27(Kip1) protein levels independently predict outcome after breast cancer[J].J Clin Oncol,2000,18(24):4045-4052.
|
| [25] |
Deng CX.BRCA1: cell cycle checkpoint, genetic instability,DNA damage response and cancer evolution[J].Nucleic Acids Res,2006,34(5):1416-1426.
|
| [26] |
Korde LA, Mueller CM, Loud JT, et al.No evidence of excess breast cancer risk among mutation-negative women from BRCA mutation-positive families[J].Breast Cancer Res Treat,2011,125(1):169-173.
|
| [27] |
Chen Y, Lee WH, Chew HK.Emerging roles of BRCA1 in transcriptional regulation and DNA repair[J].J Cell Physiol,1999,181(3):385-392.
|
| [28] |
Diamond JR, Borges VF, Eckhardt SG, et al.BRCA in breast cancer: from risk assessment to therapeutic prediction[J].Drug News Perspect,2009,22(10):603-8.
|
| [29] |
Futamura M, Arakawa H, Matsuda K, et al.Potential role of BRCA2 in a mitotic checkpoint after phosphorylation by hBUBR1[J].Cancer Res,2000,60(6):1531-1535.
|
| [30] |
Marmorstein LY, Kinev AV, Chan GK, et al.A human BRCA2 complex containing a structural DNA binding component influences cell cycle progression[J].Cell, 2001,104(2):247-257.
|
| [31] |
Mavaddat N, Pharoah PD, Blows F, et al.Familial relative risks for breast cancer by pathological subtype: a populationbased cohort study[J].Breast Cancer Res, 2010,12(1):R10.
|
| [32] |
Rao VN, Shao N, Ahmad M, et al.Antisense RNA to the putative tumor suppressor gene BRCA1 transforms mouse fibroblasts[J].Oncogene,1996,12(3):523-528.
|
| [33] |
Harkin DP, Bean JM, Miklos D, et al.Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1[J].Cell,1999,97(5):575-586.
|
| [34] |
Buck M.A novel domain of BRCA1 interacts with p53 in breast cancer cells[J].Cancer Lett,2008,268(1):137-145.
|
| [35] |
Laulier C,Barascu A,Guirouilh-Barbat J,et al.Bcl-2 inhibits nuclear homologous recombination by localizing BRCA1 to the endomembranes[J].Cancer Res,2011,71(10):3590-3602.
|
| [36] |
Einbeigi Z, Enerbäck C, Wallgren A, et al.BRCA1 gene mutations may explain more than 80% of excess number of ovarian cancer cases after breast cancer-a population based study from the Western Sweden Health Care region[J].Acta Oncol,2010,49(3):361-367.
|
| [37] |
Shan J, Dsouza SP, Bakhru S, et al.TNRC9 downregulates BRCA1 expression and promotes breast cancer aggressiveness[J].Cancer Res,2013,73(9):2840-2849.
|
| [38] |
Ingham SL, Warwick J, Buchan I, et al.Ovarian cancer among 8005 women from a breast cancer family history clinic:no increased risk of invasive ovarian cancer in families testing negative for BRCA1 and BRCA2[J].J Med Genet,2013,50(6):368-372.
|
| [39] |
Anders CK, Zagar TM, Carey LA.The management of earlystage and metastatic triple-negative breast cancer:a review[J].Hematol Oncol Clin North Am,2013,27(4):737-749.
|
| [40] |
Kennedy RD,Quinn JE,Mullan PB,et al.The role of BRCA1 in the cellular response to chemotherapy[J].J Natl Cancer Inst,2004,96(22):1659-1668.
|
| [41] |
Chalasani P, Livingston R.Differential chemotherapeutic sensitivity for breast tumors with “BRCAness”: a review[J].Oncologist,2013,18(8):909-916.
|
| [42] |
Vig HS, McCarthy AM, Liao K, et al.Age at diagnosis may trump family history in driving BRCA testing in a population of breast cancer patients[J].Cancer Epidemiol Biomarkers Prev,2013,22(10):1778-1785.
|
| [43] |
Fischer C, Kuchenbäcker K, Engel C, et al.Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium[J].J Med Genet,2013,50(6):360-367.
|
| [44] |
Mavaddat N, Peock S, Frost D, et al.Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE[J].J Natl Cancer Inst,2013,105(11):812-822.
|
| [45] |
Suchy J, Cybulski C, Górski B, et al.BRCA1 mutations and colorectal cancer in Poland[J].Fam Cancer, 2010,9(4):541-544.
|
| [46] |
Greer JB,Whitcomb DC.Role of BRCA1 and BRCA2 mutations in pancreatic cancer[J].Gut,2007,56(5):601-605.
|
| [47] |
Antoniou AC, Beesley J, McGuffog L, et al.Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction[J].Cancer Res,2010,70(23):9742-9754.
|
| [48] |
Castro E, Goh C, Olmos D, et al.Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer[J].J Clin Oncol,2013,31(14):1748-1757.
|
| [49] |
Brose MS, Rebbeck TR, Calzone KA, et al.Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program[J].J Natl Cancer Inst, 2002,94(18):1365-1372.
|